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treatment records should minimize the costs of the medical
aid. However, it is also necessary to consider the cost of
the effect achieved and quality price of not only the medi-
cal aid itself but the life quality to be created as a result of
medical intervention. The latter fact is closely connected
with the ethical and moral aspects of the medical aid. It
predetermines the obligatoriness and the content of the in-
formed patient’s consent to medical intervention that must
be a component of the patient’s treatment record. Using
the results of the pharmacoeconomic investigations and
meta-analysis that must cover not only pharmaceutical fa-
cilities but also the other diagnostic may solve the de-
scribed problems and therapeutic services as well. When
developing such a system, it is necessary to consider the
difficulties that may arise as a result of Russia’s current
practice to widely use the low-informative methods of di-
agnostics, low-efficient medicinal preparations, methods
of physical therapy, and the unavailability of medical in-
formation for the patient.
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Pharmacoeconomic studies are increasing in number
along with their use in healthcare decision-making. The
methods and analyses used in these studies are often new
to clinicians; thus, clinicians may often find it difficult to
read, interpret, assess, and use these studies in their own
decision-making when comparing products. 
OBJECTIVE: In late 1997, the American College of Neu-
ropsychopharmacology (ACNP) convened a task force
charged with developing methodological standards that
could be used to evaluate CNS-related (e.g., psychiatric,
neurologic) pharmacoeconomic studies and be used to
rate these studies. 
METHODS: The Task Force was comprised of members
of the ACNP, non-ACNP scientists, and representatives of
the pharmaceutical industry with expertise and interest in
pharmacoeconomics. The Task Force first compiled a draft
set of rating criteria from existing criteria and other guide-
lines for pharmacoeconomic studies. Two separate rounds
of feasibility tests were conducted during which Task
Force members evaluated three pharmacoeconomic studies
using the initial and the revised rating scale. 
RESULTS: To date, a working rating scale using a 6-point
Likert-type responses has been developed which includes
29 aspects of a pharmacoeconomic study over the follow-
ing seven domains: scope of study, study objectives, sam-
ple, methods, definitions, results and discussion, and con-
clusions. The scale is under consideration for use by the
ACNP pending further refinement. 
CONCLUSIONS: A rating scale has been developed by
which to assess pharmacoeconomic studies within a clini-
cal specialty area. Further testing is needed to refine the
scale and assess its psychometric properties.
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Patient-level healthcare costs are frequently estimated us-
ing claims databases or financial records (e.g., hospital
bills and institutional cost reports). However, in some
healthcare settings, particularly staff model HMOs, this
information is absent. 
OBJECTIVE: To develop a methodology for estimating
costs of healthcare services in the absence of financial
data at a staff-model HMO, using the Asthma Outcomes
Registry as a case study. 
METHODS: The Asthma Outcomes Registry compiled
clinical and economic data on individual asthmatic sub-
jects from three US managed care sites. Two sites pro-
vided data on utilization and cost of healthcare services
derived from health insurance claims. The third site, a
staff-model HMO, provided data on service utilization
but not cost. We used claims data from the two sites that
provided it to impute unit costs of services for treatment
of asthma and allergic rhinitis at the third site. Analysis
of covariance models were fitted to the logarithm of cost
per encounter (or per inpatient day) for patients with
such data, and these models were used to assign a cost
(retransformed logarithm) to each healthcare encounter
at the staff-model HMO. To preserve variation, each en-
counter’s cost was drawn randomly from the distribution
(mean and variance) estimated from the other two sites. 
RESULTS: Estimated geometric mean costs (logarithms 
standard error) of outpatient encounters for asthma and
allergic rhinitis were $78.26 ($4.36  0.014) and $66.02
($4.19  0.032), respectively. Corresponding estimates
for emergency visits and inpatient days for asthma were
$208.51 ($5.34  0.059) and $820.57 ($6.71  0.092).
Visits for allergy testing were estimated to cost $25.03
($3.22  0.009). 
CONCLUSION: Diagnosis-specific unit costs of medical
encounters can be imputed in settings where such data
are absent using data from comparable settings.
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